TriSb92 as a potential inhibitor against SARS-CoV-2 variants including Omicron

By | December 31, 2021
New findings indicate that TriSb92 is a potent inhibitor of SARS-CoV-2 infection targeting a conserved site in the RBD of the spike, which is insensitive for immune escape mutations found in the relevant variants of concern, including Omicron